Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®

被引：111

作者：

Kaku, Kohei ^{[1
]}

Lee, Jisoo ^{[2
]}

Mattheus, Michaela ^{[2
]}

Kaspers, Stefan ^{[2
]}

George, Jyothis ^{[3
]}

Woerle, Hans-Juergen ^{[2
]}

Aizenberg, D. ^{[4
]}

Ulla, M. ^{[5
]}

Waitman, J. ^{[6
]}

De Loredo, L. ^{[7
,8
]}

Farias, J. ^{[9
]}

Fideleff, H. ^{[9
]}

Lagrutta, M. ^{[10
]}

Maldonado, N. ^{[11
]}

Colombo, H. ^{[12
]}

Ferre Pacora, F. ^{[13
]}

Wasserman, A. ^{[14
]}

Maffei, L. ^{[15
]}

Lehman, R. ^{[16
]}

Selvanayagam, J. ^{[17
]}

d'Emden, M. ^{[18
]}

Fasching, P. ^{[19
]}

Paulweber, B. ^{[20
]}

Toplak, H. ^{[21
]}

Luger, A. ^{[22
]}

Drexel, H. ^{[23
]}

Prager, R. ^{[24
]}

Schnack, C. ^{[25
]}

Schernthaner, G. ^{[25
,26
]}

Fliesser-Goerzer, E.

Kaser, S. ^{[27
]}

Scheen, A. ^{[28
]}

Van Gaal, L. ^{[29
]}

Hollanders, G.

Kockaerts, Y. ^{[30
]}

Capiau, L.

Chachati, A. ^{[31
]}

Persu, A. ^{[32
]}

Hermans, M. ^{[32
]}

Vantroyen, D. ^{[33
]}

Vercammen, C. ^{[34
]}

Van de Borne, P. ^{[35
]}

Mathieu, C. ^{[36
]}

Benhalima, K. ^{[36
]}

Lienart, F. ^{[37
]}

Mortelmans, J.

Strivay, M. ^{[38
]}

Vereecken, G.

Keymeulen, B. ^{[39
]}

Lamkanfi, F. ^{[39
]}

机构：

[1] Kawasaki Med Sch, Dept Gen Internal Med, 577 Matsushima, Kurashiki, Okayama 7010192, Japan

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[4] Ctr Med Viamonte, Buenos Aires, DF, Argentina

[5] ILAIMCEOM, Cordoba, Cba, Argentina

[6] Ctr Diabetol Dr Waitman, Cordoba, Cba, Argentina

[7] Hosp Privado Ctr Med Cordoba SA, Cordoba, Cba, Argentina

[8] Parque Velez Sarfield, Cordoba, Cba, Argentina

[9] Sanatorio Guemes Hosp Privado, Buenos Aires, DF, Argentina

[10] Inst Invest Clin, Rosario, Santa Fe, Argentina

[11] Ctr Med Alta Complejidad, Rosario, Santa Fe, Argentina

[12] Clin Privada Colombo, Cordoba, Co, Argentina

[13] Ctr Med Colon, Cordoba, Co, Argentina

[14] Fepreva, Buenos Aires, DF, Argentina

[15] Consultorios Asociados Endocrinol & Invest Clin, Buenos Aires, DF, Argentina

[16] Adelaide Med Res, Ashford, SA, Australia

[17] Heart & Vasc Inst, Fullarton, SA, Australia

[18] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[19] Wilhelminenspital Wien, Vienna, Austria

[20] LKH Salzburg, St Johanns Spital, Salzburg, Austria

[21] Med Univ Graz, Graz, Austria

[22] Univ Klin Innere Med III, Vienna, Austria

[23] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[24] Krankenhaus Hietzing NZR, Vienna, Austria

[25] Krankenanstalt Rudolfstiftung Wien, Semmelweis Frauenklin, Vienna, Austria

[26] Univ Klin Innere Med II, Vienna, Austria

[27] Univ Klin Innsbruck, Innsbruck, Austria

[28] Ctr Hosp Univ Liege, Liege, Belgium

[29] UZA, Edegem, Belgium

[30] Ziekenhuis Oost Limburg, Genk, Belgium

[31] CHR Huy, Huy, Belgium

[32] Clin Univ St Luc, Brussels, Belgium

[33] Huisartsenpraktijk Hygeia, Hasselt, Belgium

[34] Imelda ZH Bonheiden, Bonheiden, Belgium

[35] Hop Univ Erasme, Brussels, Belgium

[36] Univ Hosp Gasthuisberg, Leuven, Belgium

[37] CHU Tivoli, La Louviere, Belgium

[38] CHR Citadelle, Site Citadelle, Liege, Belgium

[39] UZ Brussels, Brussels, Belgium

[40] Hosp Sao Paulo UNIFESP, Villa Clementino, SP, Brazil

[41] Ctr Pesquisas Clin Ltda, Higienopolis, SP, Brazil

[42] Hosp Rim Hipertensao, Vila Clementino, SP, Brazil

[43] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil

[44] Blumenau Serv Med SC Ltda, Vila Leopoldina, SP, Brazil

[45] Irmandade Santa Casa Misericordia Sao Paulo, Vila Albuquerque, SP, Brazil

[46] Hosp Guilherme Alvaro, Ctr Pesquisas Clin, Boqueirao, ST, Brazil

[47] Hosp Mae Deus, Porto Alegre, RS, Brazil

[48] Hosp Geral Goiania, Goiania, Go, Brazil

[49] FMUSP, Hosp Clin Sao Paulo, Sao Paulo, Brazil

[50] Univ Ribeirao Preto, Hosp Elect Bonini, Ribeirao Preto, Brazil

来源：

CIRCULATION JOURNAL | 2017年 / 81卷 / 02期

关键词：

Diabetes mellitus; Mortality; Race; Sodium-glucose cotransporter 2; Treatment outcomes; INHIBITION;

D O I：

10.1253/circj.CJ-16-1148

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race. Methods and Results: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48-0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population. Conclusions: Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.

引用

页码：227 / +

页数：11

共 50 条

[31] Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
McGuire, Darren K.
Zinman, Bernard
Inzucchi, Silvio E.
Wanner, Christoph
Fitchett, David
Anker, Stefan D.
Pocock, Stuart
Kaspers, Stefan
George, Jyothis T.
von Eynatten, Maximilian
Johansen, Odd Erik
Jamal, Waheed
Mattheus, Michaela
Elsasser, Ulrich
Hantel, Stefan
Lund, Soren S.
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : 949 - 959
[32] EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age
Krentz, Andrew J.
CARDIOVASCULAR ENDOCRINOLOGY, 2015, 4 (04): : 115 - 116
[33] Reduced progression of kidney disease with empagliflozin: results from EMPA-REG OUTCOME
Wanner, C.
Inzucchi, S.
Lachin, J. M.
Fitchett, D.
von Eynatten, M.
Mattheus, M.
Johansen, O. E.
Woerle, H. J.
Broedl, U. C.
Zinman, B.
DIABETIC MEDICINE, 2017, 34 : 80 - 81
[34] Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME
Vaduganathan, Muthiah
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Inzucchi, Silvio E.
Zinman, Bernard
Butler, Javed
CIRCULATION, 2020, 142
[35] Interrelationship Between Reduction in Weight and Adiposity Indices and Improvement in Cardiovascular Death and Heart Failure Outcomes With Empagliflozin in Patients With Type 2 Diabetes in EMPA-REG OUTCOME
Neeland, Ian J.
McGuire, Darren K.
Hehnke, Uwe
Woerle, Hans-Juergen
Fitchett, David
Johansen, Odd Erik
CIRCULATION, 2017, 136
[36] Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?
Strojek, Krzysztof
Rokicka, Dominika
Szymborska-Kajanek, Aleksandra
Wrobel, Marta
CLINICAL DIABETOLOGY, 2016, 5 (03): : 107 - 110
[37] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
Cooper, Mark E.
Inzucchi, Silvio E.
Zinman, Bernard
Hantel, Stefan
von Eynatten, Maximilian
Wanner, Christoph
Koitka-Weber, Audrey
AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
[38] Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
Inzucchi, Silvio E.
Zinman, Bernard
George, Jyothis
Mattheus, Michaela
von Eynatten, Maximilian
Wanner, Christoph
Hauske, Sibylle
DIABETES, 2019, 68
[39] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
Odutayo, Ayodele
Zinman, Bernard
Wanner, Christoph
Zwiener, Isabella
Lund, Soren S.
Hantel, Stefan
Fitchett, David
Udell, Jacob A.
CJC OPEN, 2024, 6 (07) : 868 - 875
[40] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
Verma, Subodh
Leiter, Lawrence A.
Zinman, Bernard
Sharma, Abhinav
Mattheus, Michaela
Fitchett, David
George, Jyothis
Ofstad, Anne Pernille
Kosiborod, Mikhail N.
Wanner, Christoph
Inzucchi, Silvio E.
ESC HEART FAILURE, 2021, 8 (04): : 2603 - 2607

← 1 2 3 4 5 →